跳转至内容
Merck
CN

SML0132

Sigma-Aldrich

醋酸兰瑞肽

≥98% (HPLC), SRIF-1 sst2 subtype of somatostatin receptor agonist, powder

别名:

3-(2-萘基)-D-丙氨酰基-L-半胱氨酰基-L-酪氨酸-D-色氨酸-L-赖氨酰基-L-戊酰基-L-半胱氨酰-L-苏氨酸酰胺环状(2→7)-乙酸二硫, BIM-23014C, 醋酸血管肽素

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C54H69N11O10S2 · xC2H4O2
化学文摘社编号:
127984-74-1
分子量:
1096.32 (free base basis)
UNSPSC代码:
12352200
PubChem化学物质编号:
329825182
NACRES:
NA.25

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

醋酸兰瑞肽, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to off-white

运输

wet ice

储存温度

−20°C

SMILES字符串

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

InChI key

DEXPIBGCLCPUHE-HPDHVNDUSA-N

相关类别

应用

乙酸兰瑞肽已被用作抑制剂，以测试野生型小鼠中生长激素/甲状腺激素信号转导对硫化氢调节的可变性。

生化/生理作用

八肽生长抑素类似物；sst2生长抑素受体激动剂；抗肿瘤
醋酸兰瑞肽是一种生长抑素类似物，是生长抑素受体SRIF-1 sst2亚型的选择性激动剂，对sst2的结合亲和力为0.8 nM，对sst5的结合亲和力为5.2 nM，对sst3的结合亲和力为100 nM，对于SRIF-2亚型sst1和sst4受体的结合亲和力为1000 nM以上。它在临床上可用于肢端肥大症和神经内分泌肿瘤所引起的症状的治疗，并且在最近的研究中还可以用于抑制肿瘤的生长，并显示出对非内分泌肿瘤的活性。

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361

预防措施声明

P281

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000482799
0000482779
0000482799
0000482779
0000424559

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ivan Borbath et al.
Acta gastro-enterologica Belgica, 75(2), 270-273 (2012-08-09)
We describe the case of a 54 years old woman, with hepatitis B, in whom the diagnosis of a 6 cm hepatocellular carcinoma (HCC) in the left liver was made in 2001. Alpha-foeto-protein (AFP) was 63 ng/mL (NI < 10
Maxime Palazzo et al.
European journal of gastroenterology & hepatology, 25(2), 232-238 (2012-10-31)
An antiproliferative effect of somatostatin analogs was recently demonstrated. To identify factors associated with tumor control in a group of patients with well-differentiated malignant digestive neuroendocrine tumors treated with lanreotide. A retrospective study was conducted in 68 patients treated with
Philippe J Caron et al.
The Journal of clinical endocrinology and metabolism, 99(4), 1282-1290 (2014-01-16)
Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. The aim of the study was to better characterize the effects of primary
Shaun Coughlin et al.
World journal of surgery, 36(5), 1016-1029 (2012-03-16)
Enterocutaneous fistulas are abnormal connections between the skin and gastrointestinal tract that most commonly occur after surgery. Somatostatin analogues have been used in their treatment. The objective of the present study was to determine if somatostatin analogues shorten the time
Nan Zheng et al.
Molecular pharmaceutics, 9(5), 1175-1188 (2012-03-23)
Many tumor cells specifically overexpress somatostatin receptors, in particular, subtype 2 (SSTR2). Lanreotide, a somatostatin analogue with high affinity for SSTR2, can be exploited as a ligand for tumor targeted therapy. In this study, lanreotide was first conjugated to poly(ethylene
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持